Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial

Background Improved heart failure (HF) risk stratification after a recent acute coronary syndrome may identify those who can benefit from therapies that reduce HF risk. We aimed to identify clinical and biomarker predictors for expanded HF outcomes in patients with type 2 diabetes mellitus after recent acute coronary syndrome. Methods and Results The EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial was a multicenter, non‐inferiority, double‐masked, placebo‐controlled study which randomized 5380 patients with type 2 diabetes mellitus after recent acute coronary syndrome to alogliptin or placebo. Baseline biomarkers were measured in 5154 patients: NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity troponin I, adiponectin, growth‐differentiation‐factor‐15, and galectin‐3. Our primary outcome was cardiovascular) death, HF hospitalization, elevated NT‐proBNP during follow‐up, or loop diuretics initiation. The association between clinical variables, biomarkers, and outcomes were assessed using Cox regression models. In the study population, the median age was 61.0 years, 67.7% were men, and 28.0% had baseline HF (median follow‐up was 18 months). In multivariable analyses, NT‐proBNP had the strongest association with the primary outcome (per log2, hazard ratio 1.24; Wald χ2 67.4; P<0.0001) followed by a prior HF history (hazard ratio 1.42; Wald χ2 20.8; P<0.0001). A model with clinical variables and biomarkers allowed for risk prediction for expanded HF outcomes (C‐statistic=0.72). Discrimination results were similar for cardiovascular death or HF hospitalization. Conclusions Among patients with type 2 diabetes mellitus after recent acute coronary syndrome, the use biomarkers such as N‐terminal pro‐B‐type natriuretic peptide and clinical variables enables risk stratification for expanded HF outcomes. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00968708.

[1]  Yen-Wen Wu,et al.  Relationship Between Body Mass Index, Antidiabetic Agents, and Midterm Mortality in Patients With Both Type 2 Diabetes Mellitus and Acute Coronary Syndrome , 2019, Journal of the American Heart Association.

[2]  Declare–Timi Investigators Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[3]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[4]  C. O'connor,et al.  Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. , 2018, JACC. Heart failure.

[5]  S. Solomon,et al.  Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure , 2018, Circulation.

[6]  Björn Eliasson,et al.  Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes , 2018, The New England journal of medicine.

[7]  C. Yancy,et al.  Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines–Heart Failure Registry , 2018, Circulation. Heart failure.

[8]  C. Cannon,et al.  Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial , 2018, Diabetes Care.

[9]  W. Cushman,et al.  Early and Chronic Dipeptidyl‐Peptidase‐IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial , 2018, Journal of the American Heart Association.

[10]  J. McMurray,et al.  Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction , 2018, Diabetes Care.

[11]  Jonathan H Seltzer,et al.  Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. , 2018, Journal of the American College of Cardiology.

[12]  W. Cushman,et al.  High‐sensitivity C‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial , 2017, Diabetes, obesity & metabolism.

[13]  Jacob P. Kelly,et al.  Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease , 2017, Journal of the American Heart Association.

[14]  A. Dunning,et al.  Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial , 2017, Diabetes Care.

[15]  W. Kraus,et al.  Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. , 2017, JACC. Heart failure.

[16]  J. McMurray,et al.  Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. , 2017, JACC. Heart failure.

[17]  S. Plein,et al.  Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure , 2017, Journal of the American Heart Association.

[18]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[19]  C. Yancy,et al.  Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association , 2017, Circulation.

[20]  W. Cushman,et al.  Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) , 2017, Circulation.

[21]  Marc P. Bonaca,et al.  Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial , 2016, Diabetes, obesity and metabolism.

[22]  J. Danesh,et al.  Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis , 2016 .

[23]  Natriuretic Peptides Studies Collaboration Natriuretic peptides and integrated risk assessment for cardiovascular disease : an individual-participant-data meta-analysis Natriuretic Peptides , 2016 .

[24]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[25]  S. Solomon,et al.  Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 2016, Diabetes Care.

[26]  W. Cushman,et al.  Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial , 2014, Diabetes Care.

[27]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[28]  Deepak L. Bhatt,et al.  Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry , 2015, Circulation.

[29]  W. Cushman,et al.  Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial , 2015, The Lancet.

[30]  P. Jarolim,et al.  High sensitivity cardiac troponin assays in the clinical laboratories , 2015, Clinical chemistry and laboratory medicine.

[31]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[32]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[33]  D. J. Veldhuisen,et al.  Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure , 2013, Clinical Research in Cardiology.

[34]  G. Filippatos,et al.  Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. , 2012, European heart journal.

[35]  Mario Plebani,et al.  Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. , 2012, European heart journal.

[36]  Christopher M O'Connor,et al.  Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. , 2010, Journal of the American College of Cardiology.

[37]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[38]  G. Brabant,et al.  Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.

[39]  H. Drexler,et al.  The Transforming Growth Factor-&bgr; Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury , 2006 .

[40]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[41]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.